Abarca Health And LucyRx To Merge Into Alternative To Big Three PBMs
Abarca Health and LucyRx, two privately-held independent pharmacy benefit management companies, have recently announced their merger in a bid to offer a competitive alternative to the nation’s largest PBMs and address the growing demand for more affordable prescription drug prices. This strategic move will bring together the strengths of both companies, ultimately creating a pharmacy benefit management business that will cater to over 9 million plan members across the United States.
The merger of Abarca and LucyRx is set to position the combined entity among the top 10 PBMs in terms of prescription volume managed. Despite this achievement, the new company will remain significantly smaller than the three dominant PBMs – CVS Health’s Caremark, Express Scripts (owned by Cigna), and OptumRx (owned by UnitedHealth Group) – which currently control 80% of the U.S. market. By offering a clear alternative to the traditional PBM model, Abarca and LucyRx aim to inject more competition into the market while operating in a transparent manner, free from the conflicts of interest associated with larger companies that also own health insurers, pharmacies, or other healthcare providers.
The role of pharmacy benefit managers has come under increased scrutiny in recent years, with regulatory bodies and the public calling for greater transparency and accountability in the industry. The merger between Abarca and LucyRx comes at a pivotal moment as the PBM market faces regulatory changes, rising costs of specialty drugs, and evolving client expectations. By joining forces, the two companies seek to deliver a more flexible, accountable, and affordable PBM solution that prioritizes the needs of employers, consumers, and healthcare providers.
Upon completion of the merger, Abarca and LucyRx will operate as wholly owned subsidiaries of Healthcare Revolution Partners, with both companies maintaining their individual brands. The transaction is expected to close in the third quarter of the year, subject to regulatory approvals. The CEOs of Abarca and LucyRx, Jason Borschow and David Blair, respectively, will continue to lead their respective companies and serve as co-chairs of Healthcare Revolution Partners.
The merger between Abarca and LucyRx not only signifies a significant shift in the PBM landscape but also underscores a commitment to revolutionizing healthcare delivery and improving patient outcomes. By leveraging their combined scale, technology, and expertise, the companies aim to drive total-cost-of-care savings, enhance customer experiences, and accelerate innovation in the healthcare industry.
As Abarca and LucyRx embark on this new chapter of collaboration, they are poised to make a meaningful impact on the healthcare ecosystem, setting a new standard for PBM services and paving the way for a more seamless and personalized healthcare experience for all stakeholders.
